Research Roundup: MDGs, TB vaccines, impactful innovations, budget trackers, and more
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In a United Nations Foundation blog post, Carla Koppell—chief strategy officer at the US Agency for International Development—notes that much remains to be done to achieve the Millennium Development Goals (MDGs) and argues that accelerating progress on the MDGs in the last 500 days will require harnessing the power of science, technology, and innovation.
GHTC member Aeras has announced the initiation of a large, multi-country Phase IIb clinical trial to test a novel vaccine candidate’s ability to prevent tuberculosis in adults. Aeras and GlaxoSmithKline Vaccines, S.A. will evaluate the efficacy, safety, and immunogenicity of GSK’s vaccine candidate, M72/AS01E, and will enroll more than 3,500 healthy adults ages 18-50 years old in sub-Saharan African.
The Kaiser Family Foundation has developed an interactive US global health budget tracker that will include regularly updated information on historical trends and funding levels throughout the appropriations process as it pertains to global health.
GHTC member PATH is developing the Innovative Countdown initiative to showcase the innovations the world believes have the greatest promise to accelerate progress and “bend the curve” of present trends to meet the United Nations’ Sustainable Development Goals health targets. To participate in the survey, click here.
Claire Topal, senior advisor for international health at The National Bureau of Asian Research, interviewed Rob Lin from the Infectious Disease Research Institute on the value of product development partnerships (PDPs). Lin discusses how PDPs came about, what gaps PDPs currently fill in the development of new global health tools, the costs associated with development new health products, and the various collaborations PDPs are involved in to maximize the impact of their work.